Prof Noreen Starling

I was in the room, thousands of listeners in the room as the data were presented.

What we saw was a major breakthrough for the treatment of pancreatic cancer, and the results were so stunning that the presenter received a standing ovation as he was presenting the data, not even at the end of the presentation.

So half of the patients received another chemotherapy and half of the patients received the oral tablet therapy and the results were just jaw-dropping.

So in this group of patients, survival was doubled, going for an average of about six months to over 13 months.

We saw tumour shrink in the patients who have the Dyraxone RACIP tablets, a good shrinkage of over 30% of patients compared to about 10% of patients with chemotherapy.

And really importantly for patients, not only were they living longer, but they felt better.

There was a reduction in pain and improvement in symptoms for a good amount of time.

The way it works is very clever and it's quite different to sort of the traditional drug inhibitor.

So a drug interacts with the protein that you want and shuts it down.

It does it in a more sneaky way.

So it binds to a chaperone protein called cyclophenol A and forms a bond with that.

And then that doublet, if you like, blocks the activated state of Ras.

It's forming a kind of molecular glue to shut Ras down and stop it providing the signal for the cancer cell to grow.

There are so many more important questions now for our patients with pancreatic cancer.

So the trial is very specifically for the group of patients who've had chemotherapy previously and it has stopped working.

One of the next important questions is, okay, what about the patients who've just been diagnosed with advanced stage four pancreatic cancer?

Does dyraxonracib, this oral therapy, work for those patients?

Does it improve survival and symptoms and how patients feel as the first line of treatment?

But then going back to how do we actually prevent pancreatic cancer becoming advanced, what about those patients with operable pancreatic cancer and

But it doesn't stop there.